Billions on the line: BioMarin bustles past enthused rival, planning to launch world’s first hemophilia A gene therapy
BioMarin isn’t going to let a rival’s success over the weekend get in the way of making a bee-line to the FDA with an imperfect, but presentable, gene therapy for hemophilia A.
On Monday the biotech $BMRN reported that its talks with the FDA and the EMA convinced execs to make a leap for an accelerated approval with data on just a handful of patients. And they’re handing over Phase I/II and interim Phase III results in Q4 to make their case.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.